Price chart
Loading 1Y daily…
Financial overlay · last 12 quarters
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3.6B | $0.7B | $0.7B | $0.8B | 20.2% | 20.7% |
| 2025-12-31 | $3.9B | $0.8B | $0.9B | $0.9B | 21.7% | 23.1% |
| 2025-09-30 | $3.8B | $1.5B | $1.1B | $1.4B | 38.9% | 29.6% |
| 2025-06-30 | $3.7B | $1.4B | $1.1B | $0.7B | 37.9% | 29.4% |
| 2025-03-31 | $3.0B | $0.8B | $0.6B | $0.8B | 26.7% | 19.5% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
| 2024-09-30 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Earnings replay · last 20 reports
| Date | EPS actual | EPS est | Surprise |
|---|---|---|---|
| 2026-04-29 | 6.75 | 8.60 | -21.5% |
| 2026-01-30 | 7.86 | 9.14 | -14.0% |
| 2025-10-28 | 11.83 | 9.64 | +22.7% |
| 2025-08-01 | 12.89 | 8.44 | +52.7% |
| 2025-04-29 | 7.27 | 7.06 | +3.0% |
| 2025-02-04 | 8.06 | 9.07 | -11.1% |
| 2024-10-31 | 12.46 | 11.70 | +6.5% |
| 2024-08-01 | 11.56 | 10.62 | +8.8% |
| 2024-05-02 | 9.55 | 10.10 | -5.4% |
| 2024-02-02 | 11.86 | 10.75 | +10.4% |
| 2023-11-02 | 11.59 | 10.78 | +7.6% |
| 2023-08-03 | 10.24 | 9.90 | +3.5% |
| 2023-05-04 | 10.09 | 9.56 | +5.5% |
| 2023-02-03 | 12.56 | 10.01 | +25.5% |
| 2022-11-03 | 11.14 | 9.48 | +17.6% |
| 2022-08-03 | 9.77 | 8.76 | +11.6% |
| 2022-05-04 | 11.49 | 9.80 | +17.3% |
| 2022-02-04 | 23.72 | 20.30 | +16.9% |
| 2021-11-04 | 15.37 | 9.94 | +54.6% |
| 2021-08-05 | 25.80 | 17.71 | +45.7% |
Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).
Peer comparison · Healthcare
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| REGN ★ | $64B | 14.8 | 11.3 | 4.3 | 12.6 | 2.0 | 43.9% | 19.0% | -7.2% | 5.14% |
| LLY | $954B | 37.9 | 24.1 | 13.2 | 27.3 | 30.6 | 82.8% | 55.5% | 169.9% | 0.96% |
| UNH | $350B | 29.1 | 18.5 | 0.8 | 18.5 | 3.6 | 18.8% | 2.0% | 0.7% | 5.05% |
| JNJ | $538B | 25.9 | 17.6 | 5.6 | 16.6 | 6.6 | 68.0% | 9.9% | -52.9% | 2.32% |
| MRK | $288B | 32.8 | 12.2 | 4.4 | 11.2 | 6.3 | 76.7% | 4.9% | — | 4.88% |
| ABBV | $383B | 105.9 | 13.4 | 6.1 | 14.8 | -57.6 | 72.0% | 12.4% | -46.2% | 5.43% |
| PFE | $146B | 19.5 | 9.0 | 2.3 | 7.8 | 1.6 | 74.8% | 5.4% | -10.1% | 8.50% |
| TMO | $175B | 26.0 | 17.3 | 3.9 | 19.4 | 3.3 | 40.9% | 6.2% | 11.3% | 3.15% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Top institutional holders
Top-10 concentration: 39.34%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 8,947,735 | 8.69% |
| Vanguard Capital Management LLC | 6,654,913 | 6.46% |
| State Street Corporation | 4,664,478 | 4.53% |
| Dodge & Cox Inc. | 4,458,238 | 4.33% |
| JPMORGAN CHASE & CO | 4,311,806 | 4.19% |
| Franklin Resources, Inc. | 2,722,071 | 2.64% |
| Geode Capital Management, LLC | 2,607,732 | 2.53% |
| Price (T.Rowe) Associates Inc | 2,177,527 | 2.11% |
| Nuveen, LLC | 2,065,064 | 2.00% |
| LOOMIS SAYLES & CO L P | 1,912,310 | 1.86% |
Insider activity · 90d
No insider trades for REGN in last 90d.
Analyst estimates
yfinanceConsensus: buy (mean 1.72414). Distribution requires FINNHUB_API_KEY.
SEC filings
| Form | Filed | Description | Action |
|---|---|---|---|
| 13F-HR | 2026-05-08 | Institutional holdings (13F) | view · |
| 4 | 2026-05-04 | PRIMARY DOCUMENT | view · |
| 10-Q | 2026-04-29 | 10-Q | view · |
| 8-K | 2026-04-29 | 8-K | view · |
| DEF 14A | 2026-04-24 | DEFINITIVE PROXY STATEMENT | view · |
| 8-K | 2026-04-08 | FORM 8-K | view · |
| 4 | 2026-04-03 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-03-03 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-23 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-11 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-11 | PRIMARY DOCUMENT | view · |
| 13F-HR | 2026-02-06 | Institutional holdings (13F) | view · |
| 10-K | 2026-02-04 | 10-K | view · |
| 8-K | 2026-01-30 | 8-K | view · |
| 8-K | 2026-01-12 | FORM 8-K | view · |
| 4 | 2026-01-08 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-05 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-05 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-31 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-11 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-11 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-11 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-11 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-11 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-09 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-09 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-09 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-09 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-09 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-09 | PRIMARY DOCUMENT | view · |
| 4 | 2025-11-24 | PRIMARY DOCUMENT | view · |
| 4 | 2025-11-24 | PRIMARY DOCUMENT | view · |
| 4 | 2025-11-10 | PRIMARY DOCUMENT | view · |
| 13F-HR | 2025-11-07 | Institutional holdings (13F) | view · |
| 4 | 2025-10-31 | PRIMARY DOCUMENT | view · |
| 4 | 2025-10-31 | PRIMARY DOCUMENT | view · |
| 10-Q | 2025-10-28 | 10-Q | view · |
| 8-K | 2025-10-28 | 8-K | view · |
| 8-K | 2025-10-06 | FORM 8-K | view · |
| 13F-HR | 2025-08-01 | Institutional holdings (13F) | view · |
| 10-Q | 2025-08-01 | 10-Q | view · |
| 8-K | 2025-08-01 | 8-K | view · |
| 8-K | 2025-06-18 | FORM 8-K | view · |
| 13F-HR | 2025-05-02 | Institutional holdings (13F) | view · |
| 10-Q | 2025-04-29 | 10-Q | view · |
| 8-K | 2025-04-29 | 8-K | view · |
| DEF 14A | 2025-04-29 | DEFINITIVE PROXY STATEMENT | view · |
| 13F-HR | 2025-02-07 | Institutional holdings (13F) | view · |
| 10-K | 2025-02-05 | 10-K | view · |
About
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology…